Home > Boards > US Listed > Biotechs > Autolus Therapeutics plc (AUTL)

The FDA has accepted the IND application for

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 17
Posts 1,269
Boards Moderated 1
Alias Born 10/24/15
160x600 placeholder
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 1/8/2021 4:16:40 PM
Autolus Therapeutics provides business outlook for 2021 & 2022 GlobeNewswire Inc. - 1/6/2021 4:07:15 AM
Autolus Therapeutics to participate in Investor Conferences through January GlobeNewswire Inc. - 1/4/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/7/2020 4:02:13 PM
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting GlobeNewswire Inc. - 12/7/2020 12:01:00 PM
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) dur... GlobeNewswire Inc. - 12/5/2020 3:01:00 PM
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medi... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in ... GlobeNewswire Inc. - 11/17/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/5/2020 4:04:54 PM
Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 11/5/2020 7:00:00 AM
Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5 GlobeNewswire Inc. - 10/30/2020 7:00:10 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/18/2020 8:01:56 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/18/2020 7:12:50 AM
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020 GlobeNewswire Inc. - 9/18/2020 3:05:10 AM
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking c... GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/27/2020 6:04:02 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/13/2020 4:10:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 4:07:57 PM
Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Autolus announces changes to its Board and Management Team GlobeNewswire Inc. - 8/4/2020 7:00:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/3/2020 4:13:33 PM
Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6 GlobeNewswire Inc. - 7/30/2020 7:00:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/20/2020 4:10:57 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/6/2020 4:16:26 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 6/30/2020 4:14:54 PM
jondoeuk   Wednesday, 04/22/20 09:10:20 PM
Re: None
Post # of 19 
The FDA has accepted the IND application for AUTO1, for the treatment of adults with acute lymphoblastic leukemia. The active IND allows initiation of the US sites in the company's first pivotal trial (AUTO1-AL1). The AUTO1-AL1 trial application was approved by the MHRA in Jan and the first site opened in the UK in March. The COVID-19 situation has had varying degrees of impact on the ability of clinical sites to operate normally; however, based on current expectations, the company anticipates that the impact on the AUTO1-AL1 trial will be minimal. The trial has a run in phase, with a small number of patients scheduled to be enrolled into the study in Q2, limiting the impact from the COVID-19 situation at this stage. The company has continued to manufacture, without interruption, from its operations at the Cell and Gene Therapy Catapult located in Stevenage, UK, including supply to the US of clinical products for the treatment of DLBCL patients in its AUTO3 trial.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences